Navigation Links
Phase II Study of Zevalin(R) Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 89 Percent Three-Year Progression Free Survival in Patients with Previously Untreated Non-Follicular Indolent
Date:1/22/2008

Phase II Investigational Trial Published in CANCER: the Journal of the

American Cancer Society

SEATTLE, Jan. 22 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC; MTAX) announced today that results of a phase II clinical study, published in the journal CANCER demonstrate that the addition of radioimmunotherapy (RIT) to chemotherapy for previously untreated patients with non-follicular indolent non-Hodgkin's lymphoma (NHL) was both well tolerated and effective, producing a 100 percent complete remission at end of treatment with an estimated 89 percent of patients remaining in remission at three years.

The study, conducted at the Institute of Hematology and Medical Oncology at University of Bologna, Italy, investigated the use of a single dose of Zevalin(R) (Ibritumomab Tiuxetan) as consolidation therapy following treatment with a regimen of fludarabine and mitoxantrone (FM chemotherapy) among 26 patients with newly diagnosed non-follicular indolent NHL. Non-follicular lymphomas are also referred to as intermediate grade compared to the low grade follicular or high grade diffuse B cell variety. FM chemotherapy resulted in 50 percent of patients achieving a complete remission (CR) and 30 percent achieving a partial remission (PR). Of the 20 patients (13 with CR and 7 with PR) who were evaluable for Zevalin consolidation, 100 percent obtained a CR at the end of treatment. With a median follow up of 20 months, the estimated three-year progression free survival (PFS) was 89.5 percent. The most common greater than or equal to grade 3 toxicities included neutropenia (11 patients) and thrombocytopenia (16 patients).

"This single arm, non-randomized phase II trial provides addition
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Genaera Begins Dosing Second Phase 1 Trial of Type 2 Diabetes and Obesity Compound Trodusquemine (MSI-1436)
2. Vical Receives Payment from AnGes MG for Allovectin-7(R) Phase 3 Pivotal Trial
3. Cerimon Pharmaceuticals Initiates Phase II/III Clinical Studies to Evaluate its Diclofenac Patch for Mild to Moderate Pain
4. CeNeRx BioPharma Announces Successful Completion of Phase l Clinical Program for Novel Antidepressant Agent Tyrima(TM)
5. Morria Biopharmaceuticals Plc Announces Preliminary Safety and Tolerability Results From Its Phase I Clinical Study of MRX-4 in Allergic Rhinitis Patients
6. SGX Initiates Phase I Trials for SGX523
7. Fundamental Applied Biology, Inc. Is Awarded SBIR Phase IIB Grant for the Commercialization of Protein Therapeutics Using Cell Free Technology
8. Anthera Announces Preliminary Positive Results From Once-Daily A-002 Phase II Cardiovascular Trial
9. Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus Erythematosus
10. Isolagen Inc. Completes Injections of Isolagen Therapy(TM) in Phase III Wrinkle and Phase II Full Face Studies
11. First Patient Enrolled in Cogentus Pharmaceuticals Pivotal Phase 3 Trial of Novel Combination Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... privately held medical device company, announced today that it ... Corporation (Tokyo Stock Exchange TYO: 8001) to sell its ... in Japan . ViewRay,s technology, the ... MRI-guided radiation therapy system that images and treats cancer ...
(Date:1/22/2015)...  Amgen (NASDAQ: AMGN ) today announced that it will ... Tuesday, Jan. 27, 2015, after the close of the U.S. financial ... the investment community at 2 p.m. PT. Participating in the call ... chief executive officer, and other members of Amgen,s senior management team. ...
(Date:1/22/2015)... 22, 2015 Research and Markets ( ... "Microbiology Testing/Clinical Microbiology Market by Product, Clinical ... 2019" report to their offering. ... techniques for the detection of infectious diseases. The ...
Breaking Medicine Technology:ITOCHU Named the Exclusive Distributor for ViewRay's MRI-Guided Radiation Therapy System in Japan 2Amgen Announces Webcast of 2014 Fourth Quarter and Full Year Financial Results 2Global Microbiology Testing/Clinical Microbiology (Instrument, Analyzer, Incubator, Kit, Microscope, Molecular Diagnostics) Market - Forecast to 2019 2Global Microbiology Testing/Clinical Microbiology (Instrument, Analyzer, Incubator, Kit, Microscope, Molecular Diagnostics) Market - Forecast to 2019 3
... Adeona Pharmaceuticals, Inc. (AMEX: AEN ), a ... reported its second quarter 2011 financial results for the period ended ... the second quarter. Updates since the beginning of ... Multiple Sclerosis (MS) ...
... Aug. 15, 2011 /PRNewswire-Asia-FirstCall/ -- Lotus Pharmaceuticals, Inc. (OTCBB: ... and seller of medicine and drugs in the People,s ... for the quarter ended June 30, 2011. Summary financial ... Quarter Financial Highlights Revenues for ...
Cached Medicine Technology:Adeona Reports Second Quarter 2011 Financial Results 2Adeona Reports Second Quarter 2011 Financial Results 3Adeona Reports Second Quarter 2011 Financial Results 4Adeona Reports Second Quarter 2011 Financial Results 5Adeona Reports Second Quarter 2011 Financial Results 6Adeona Reports Second Quarter 2011 Financial Results 7Adeona Reports Second Quarter 2011 Financial Results 8Adeona Reports Second Quarter 2011 Financial Results 9Lotus Pharmaceuticals Announces Second Quarter Fiscal 2011 Financial Results 2Lotus Pharmaceuticals Announces Second Quarter Fiscal 2011 Financial Results 3Lotus Pharmaceuticals Announces Second Quarter Fiscal 2011 Financial Results 4Lotus Pharmaceuticals Announces Second Quarter Fiscal 2011 Financial Results 5Lotus Pharmaceuticals Announces Second Quarter Fiscal 2011 Financial Results 6Lotus Pharmaceuticals Announces Second Quarter Fiscal 2011 Financial Results 7
(Date:1/22/2015)... 2015 Carinsurancesavings.biz has released a new blog ... dismemberment insurance . , Purchasing an accidental death and ... advantageous. This type of rider provides benefits if the insured ... considered a lesser form of life insurance. , AD&D ...
(Date:1/22/2015)... 2015 A study recently published ... journal Medicine & Science in Sports & Exercise ... help reduce gastrointestinal (GI) problems associated with physical ... in the double-blind, placebo-controlled study took 10 grams ...
(Date:1/22/2015)... has added many trendy Champagne wedding dresses to ... the past three years. Today, the business announces a special ... the sales manager of the company, this is on the ... point can be reflected on the discounted wedding dresses from ...
(Date:1/22/2015)... Four years since the release of their debut recording ... marriage of Avasa & Matthew Love – the duo are pleased ... release through White Swan Records on February 24, 2015. , THE ... path available to all of us to walk out of the ...
(Date:1/22/2015)... EBSCO Information Services (EBSCO) and the ... an effort to further promote visibility and adoption of the ... made AMA journals available via its subscription services, EBSCO will ... , Long known as both a subscription agency ...
Breaking Medicine News(10 mins):Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4Health News:EBSCO Expands Partnership with the American Medical Association 2Health News:EBSCO Expands Partnership with the American Medical Association 3Health News:EBSCO Expands Partnership with the American Medical Association 4
... issues, 100 percent fruit and vegetable juices do help ... a study by European researchers. ,Juices are ... their whole fruit/vegetable counterparts say several researchers in the ... analyzed a variety of studies that looked at risk ...
... Swedish researchers have found out that consuming the right type ... children are habituated to consume lesser quantities// of unsaturated fat ... healthy children in the age group of four was undertaken ... with good socio-economic background. ,This study revealed that ...
... Yanagisawa, the Health minister of Japan came in for a lot ... birth-giving machines’ in the context of describing women//. ,The ... at a local political meeting last Saturday, when the gaffe occurred. ... 15 and 50 is fixed. Because the number of birth-giving machines ...
... hit by Tsunami in 2004, the UNICEF has built 226 ... major brunt of Tsunami which ravaged many countries and islands. ... establishing mother and child care centers, UNICEF aims to provide ... land. ,According to UNICEF's Chief of Field Office ...
... waistlines expand, so does the number of people seeking liposuction ... Association of Aesthetic Plastic Surgeons (BAAPS) gives figures of at ... last year, as being liposuction procedures. This is ... most popular ‘fixes’ include areas of the breast and eyelids ...
... government funded study finds that CT scans used in emergency ... replaced by MRI scans which are better in identifying any ... be passed to magnetic resonance imaging,” wrote Dr. Geoffrey A. ... in a note accompanying the study report. ,Doctors ...
Cached Medicine News:Health News:Benefits of Fruit and Vegetable Juices 2Health News:Liposuction, Quick Fixes for the Obese 2
Blunt tipped forceps wlth a small grasping platform on each tip. For grasping fine membranes or grasping membranes adherent to the retinal surface....
Blunt tipped forceps with a smooth, pliable silicone coating on the entire interior surface of the tip. For removal of foreign bodies or atraumatic tissue grasping....
Blunt tipped forceps with small, slightly rounded tips angled perpendicular to the shaft. For grasping peripheral membranes....
Blunt tipped forceps with small, slightly pointed grasping platforms on each tip. For general purpose (fine) membrane grasping and grasping membranes adherent to the retlnal surface....
Medicine Products: